1OT.F Ovid Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
2.46 EUR
Close of Nov 12, 2026
0.9700 2.64
Market cap
EUR 464M
P/E
-
P/B
2.64x
ROE
-30.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1OT.F undervalued?

Graham number

The Graham number of Ovid Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ovid Therapeutics Inc fundamental analysis

No fundamental analysis for Ovid Therapeutics Inc yet.

Ovid Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clini…

Full company profile